artenimol has been researched along with imatinib mesylate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, J; Shen, P; Wu, X; Zhang, G; Zhang, X | 1 |
| Chien, HD; Kesely, KR; Low, PS; Noomuna, P; Pantaleo, A; Putt, KS; Tuan, TA; Turrini, FM | 1 |
1 trial(s) available for artenimol and imatinib mesylate
| Article | Year |
|---|---|
Imatinib augments standard malaria combination therapy without added toxicity.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Fever; Humans; Imatinib Mesylate; Malaria, Falciparum; Middle Aged; Quinolines; Treatment Outcome; Vietnam; Young Adult | 2021 |
1 other study(ies) available for artenimol and imatinib mesylate
| Article | Year |
|---|---|
Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
Topics: Antimalarials; Apoptosis; Artemisinins; Benzamides; Caspase 3; Caspase 9; Cell Line, Tumor; Cytochromes c; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Mitochondria; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; RNA, Messenger | 2013 |